In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Human Genome Sciences, Inc.

http://www.hgsi.com

Latest From Human Genome Sciences, Inc.

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

Deal Watch Business Strategies

Bausch Investors Initially Pessimistic Following B+L Spinout

With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.

Sales & Earnings Business Strategies

Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business

Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.

Sales & Earnings Business Strategies

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Deal Watch Business Strategies
See All

Company Information

UsernamePublicRestriction

Register